FOLFIRI-aflibercept chemotherapy is indicated in second-line treatment of metastatic colorectal cancer (mCRC) after progression under FOLFOX (±bevacizumab). Nevertheless, its proven therapeutic efficacy in clinical trials was based on partial responses. And to date, only 2 cases of complete response assessed by CT were reported in literature. We report a complete metabolic response assessed by FDG PET/CT in a 50-year-old woman with mCRC treated by FOLFIRI-aflibercept. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.
From the Departments of *Oncology,
‡Nuclear Medicine, University Hospital of Brest; and
§EA 3878 GETBO, IFR 148, Bretagne Loire University, Brest, France.
Received for publication December 2, 2018; revision accepted March 26, 2019.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Karim Amrane, MD, Department of Oncology, University Hospital of Brest, 2 Ave Foch, 29609 Brest Cedex, France. E-mail: email@example.com.
Online date: May 17, 2019